Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers-Orchestra Project

Concepción Violán^{1

2

3

4

5

6}, Lucía A Carrasco-Ribelles^{1

3

4}, Giulia Collatuzzo⁷, Giorgia Ditano⁷, Mahsa Abedini⁷, Christian Janke⁸, Christina Reinkemeyer⁸, Le Thi Thu Giang⁹, Filippo Liviero¹⁰, Maria Luisa Scapellato¹¹, Marcella Mauro¹², Francesca Rui¹², Stefano Porru^{13

14}, Gianluca Spiteri¹³, Maria Grazia Lourdes Monaco¹³, Angela Carta^{13

14}, Marina Otelea¹⁵, Agripina Rascu¹⁵, Eleonóra Fabiánová^{16

17}, Zuzana Klöslová^{16

17}, Paolo Boffetta⁷, Pere Torán-Monserrat^{1

2

5

18

19}

Affiliations

¹ Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain.
² Germans Trias i Pujol Research Institute (IGTP), Camí de les Escoles, s/n, 08916 Badalona, Spain.
³ Grup de REcerca en Impacte de les Malalties Cròniques i les Seves Trajectòries (GRIMTra) (2021 SGR 01537), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.
⁴ Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS) (RD21/0016/0029), Insitituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain.
⁵ Direcció d'Atenció Primària Metropolitana Nord Institut Català de Salut, Ctra. de Barcelona, 473, Sabadell, 08204 Barcelona, Spain.
⁶ Universitat Autónoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Spain.
⁷ Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
⁸ Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Leopoldstraße 5, 80802 Munich, Germany.
⁹ Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstrasse 4, 80337 Munich, Germany.
¹⁰ Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy.
¹¹ Occupational Medicine Unit, University Hospital of Padova, 35128 Padova, Italy.
¹² Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy.
¹³ Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy.
¹⁴ Section of Occupational Health, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.
¹⁵ University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
¹⁶ Occupational Health Department, Regional Authority of Public Health, 97556 Banská Bystrica, Slovakia.
¹⁷ Public Health Department, Faculty of Health, Catholic University, 03401 Ružomberok, Slovakia.
¹⁸ Department of Medicine, Faculty of Medicine, Universitat de Girona, 17001 Girona, Spain.
¹⁹ Multidisciplinary Research Group in Health and Society (GREMSAS) (2021 SGR 01484), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.

PMID: 37631908
PMCID: PMC10459685
DOI: 10.3390/vaccines11081340

Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers-Orchestra Project

Concepción Violán et al. Vaccines (Basel). 2023.

. 2023 Aug 8;11(8):1340.

doi: 10.3390/vaccines11081340.

Authors

Affiliations

¹ Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Mataró, Spain.
² Germans Trias i Pujol Research Institute (IGTP), Camí de les Escoles, s/n, 08916 Badalona, Spain.
³ Grup de REcerca en Impacte de les Malalties Cròniques i les Seves Trajectòries (GRIMTra) (2021 SGR 01537), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.
⁴ Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS) (RD21/0016/0029), Insitituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029 Madrid, Spain.
⁵ Direcció d'Atenció Primària Metropolitana Nord Institut Català de Salut, Ctra. de Barcelona, 473, Sabadell, 08204 Barcelona, Spain.
⁶ Universitat Autónoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Spain.
⁷ Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
⁸ Division of Infectious Diseases and Tropical Medicine, LMU Klinikum, Leopoldstraße 5, 80802 Munich, Germany.
⁹ Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstrasse 4, 80337 Munich, Germany.
¹⁰ Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy.
¹¹ Occupational Medicine Unit, University Hospital of Padova, 35128 Padova, Italy.
¹² Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34129 Trieste, Italy.
¹³ Occupational Medicine Unit, University Hospital of Verona, 37134 Verona, Italy.
¹⁴ Section of Occupational Health, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy.
¹⁵ University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
¹⁶ Occupational Health Department, Regional Authority of Public Health, 97556 Banská Bystrica, Slovakia.
¹⁷ Public Health Department, Faculty of Health, Catholic University, 03401 Ružomberok, Slovakia.
¹⁸ Department of Medicine, Faculty of Medicine, Universitat de Girona, 17001 Girona, Spain.
¹⁹ Multidisciplinary Research Group in Health and Society (GREMSAS) (2021 SGR 01484), Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mare de Déu de Guadalupe, 08303 Barcelona, Spain.

PMID: 37631908
PMCID: PMC10459685
DOI: 10.3390/vaccines11081340

Abstract

Understanding antibody persistence concerning multimorbidity is crucial for vaccination policies. Our goal is to assess the link between multimorbidity and serological response to SARS-CoV-2 nine months post-first vaccine. We analyzed Healthcare Workers (HCWs) from three cohorts from Italy, and one each from Germany, Romania, Slovakia, and Spain. Seven groups of chronic diseases were analyzed. We included 2941 HCWs (78.5% female, 73.4% ≥ 40 years old). Multimorbidity was present in 6.9% of HCWs. The prevalence of each chronic condition ranged between 1.9% (cancer) to 10.3% (allergies). Two regression models were fitted, one considering the chronic conditions groups and the other considering whether HCWs had diseases from ≥2 groups. Multimorbidity was present in 6.9% of HCWs, and higher 9-months post-vaccine anti-S levels were significantly associated with having received three doses of the vaccine (RR = 2.45, CI = 1.92-3.13) and with having a prior COVID-19 infection (RR = 2.30, CI = 2.15-2.46). Conversely, lower levels were associated with higher age (RR = 0.94, CI = 0.91-0.96), more time since the last vaccine dose (RR = 0.95, CI = 0.94-0.96), and multimorbidity (RR = 0.89, CI = 0.80-1.00). Hypertension is significantly associated with lower anti-S levels (RR = 0.87, CI = 0.80-0.95). The serological response to vaccines is more inadequate in individuals with multimorbidity.

Keywords: COVID-19; IgG; SARS-CoV-2; antibodies; cohort; healthcare workers; humoral immunity; multimorbidity; seroprevalence; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
1. Oliver S.E., Gargano J.W., Scobie H., Wallace M., Hadler S.C., Leung J., Blain A.E., McClung N., Campos-Outcalt D., Morgan R.L., et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine. MMWR Surveill. Summ. 2021;70:329–332. - PMC - PubMed
1. Bubar K.M., Reinholt K., Kissler S.M., Lipsitch M., Cobey S., Grad Y.H., Larremore D.B. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371:916–921. doi: 10.1126/science.abe6959. - DOI - PMC - PubMed
1. Català M., Coma E., Alonso S., Andrés C., Blanco I., Antón A., Bordoy A.E., Cardona P.J., Fina F., Martró E., et al. Transmissibility, hospitalization, and intensive care admissions due to omicron compared to delta variants of SARS-CoV-2 in Catalonia: A cohort study and ecological analysis. Front. Public Health. 2022;10:961030. doi: 10.3389/fpubh.2022.961030. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers-Orchestra Project

Affiliations

Multimorbidity and Serological Response to SARS-CoV-2 Nine Months after 1st Vaccine Dose: European Cohort of Healthcare Workers-Orchestra Project

Authors

Affiliations

Abstract

Conflict of interest statement

References

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous